4wey: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
No edit summary |
||
| (4 intermediate revisions by the same user not shown) | |||
| Line 1: | Line 1: | ||
==Crystal structure of E.Coli DsbA in complex with compound 17== | |||
<StructureSection load='4wey' size='340' side='right'caption='[[4wey]], [[Resolution|resolution]] 1.55Å' scene=''> | |||
== Structural highlights == | |||
<table><tr><td colspan='2'>[[4wey]] is a 2 chain structure with sequence from [https://en.wikipedia.org/wiki/Escherichia_coli_BL21(DE3) Escherichia coli BL21(DE3)]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=4WEY OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol=4WEY FirstGlance]. <br> | |||
</td></tr><tr id='method'><td class="sblockLbl"><b>[[Empirical_models|Method:]]</b></td><td class="sblockDat" id="methodDat">X-ray diffraction, [[Resolution|Resolution]] 1.55Å</td></tr> | |||
<tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat" id="ligandDat"><scene name='pdbligand=EDO:1,2-ETHANEDIOL'>EDO</scene>, <scene name='pdbligand=EG6:N-({4-METHYL-2-[4-(TRIFLUOROMETHYL)PHENYL]-1,3-THIAZOL-5-YL}CARBONYL)-L-SERINE'>EG6</scene></td></tr> | |||
<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=4wey FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=4wey OCA], [https://pdbe.org/4wey PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=4wey RCSB], [https://www.ebi.ac.uk/pdbsum/4wey PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=4wey ProSAT]</span></td></tr> | |||
</table> | |||
== Function == | |||
[https://www.uniprot.org/uniprot/A0A0H2UL03_ECOBD A0A0H2UL03_ECOBD] | |||
<div style="background-color:#fffaf0;"> | |||
== Publication Abstract from PubMed == | |||
The thiol-disulfide oxidoreductase enzyme DsbA catalyzes the formation of disulfide bonds in the periplasm of Gram-negative bacteria. DsbA substrates include proteins involved in bacterial virulence. In the absence of DsbA, many of these proteins do not fold correctly, which renders the bacteria avirulent. Thus DsbA is a critical mediator of virulence and inhibitors may act as antivirulence agents. Biophysical screening has been employed to identify fragments that bind to DsbA from Escherichia coli. Elaboration of one of these fragments produced compounds that inhibit DsbA activity in vitro. In cell-based assays, the compounds inhibit bacterial motility, but have no effect on growth in liquid culture, which is consistent with selective inhibition of DsbA. Crystal structures of inhibitors bound to DsbA indicate that they bind adjacent to the active site. Together, the data suggest that DsbA may be amenable to the development of novel antibacterial compounds that act by inhibiting bacterial virulence. | |||
Application of Fragment-Based Screening to the Design of Inhibitors of Escherichia coli DsbA.,Adams LA, Sharma P, Mohanty B, Ilyichova OV, Mulcair MD, Williams ML, Gleeson EC, Totsika M, Doak BC, Caria S, Rimmer K, Horne J, Shouldice SR, Vazirani M, Headey SJ, Plumb BR, Martin JL, Heras B, Simpson JS, Scanlon MJ Angew Chem Int Ed Engl. 2014 Dec 30. doi: 10.1002/anie.201410341. PMID:25556635<ref>PMID:25556635</ref> | |||
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.<br> | |||
[[Category: | </div> | ||
[[Category: | <div class="pdbe-citations 4wey" style="background-color:#fffaf0;"></div> | ||
[[Category: | == References == | ||
[[Category: | <references/> | ||
[[Category: | __TOC__ | ||
[[Category: | </StructureSection> | ||
[[Category: Heras | [[Category: Large Structures]] | ||
[[Category: | [[Category: Adams LA]] | ||
[[Category: | [[Category: Caria S]] | ||
[[Category: | [[Category: Doak BC]] | ||
[[Category: | [[Category: Gleeson EC]] | ||
[[Category: | [[Category: Headey SJ]] | ||
[[Category: | [[Category: Heras B]] | ||
[[Category: | [[Category: Ilyichova OV]] | ||
[[Category: | [[Category: Martin JL]] | ||
[[Category: | [[Category: Mohanty B]] | ||
[[Category: | [[Category: Mulcair MD]] | ||
[[Category: | [[Category: Plumb BR]] | ||
[[Category: | [[Category: Rimmer K]] | ||
[[Category: | [[Category: Scanlon MJ]] | ||
[[Category: Sharma P]] | |||
[[Category: Shouldice SR]] | |||
[[Category: Simpson JS]] | |||
[[Category: Totsika M]] | |||
[[Category: Vazirani M]] | |||
[[Category: Williams ML]] | |||
Latest revision as of 18:22, 8 November 2023
Crystal structure of E.Coli DsbA in complex with compound 17Crystal structure of E.Coli DsbA in complex with compound 17
Structural highlights
FunctionPublication Abstract from PubMedThe thiol-disulfide oxidoreductase enzyme DsbA catalyzes the formation of disulfide bonds in the periplasm of Gram-negative bacteria. DsbA substrates include proteins involved in bacterial virulence. In the absence of DsbA, many of these proteins do not fold correctly, which renders the bacteria avirulent. Thus DsbA is a critical mediator of virulence and inhibitors may act as antivirulence agents. Biophysical screening has been employed to identify fragments that bind to DsbA from Escherichia coli. Elaboration of one of these fragments produced compounds that inhibit DsbA activity in vitro. In cell-based assays, the compounds inhibit bacterial motility, but have no effect on growth in liquid culture, which is consistent with selective inhibition of DsbA. Crystal structures of inhibitors bound to DsbA indicate that they bind adjacent to the active site. Together, the data suggest that DsbA may be amenable to the development of novel antibacterial compounds that act by inhibiting bacterial virulence. Application of Fragment-Based Screening to the Design of Inhibitors of Escherichia coli DsbA.,Adams LA, Sharma P, Mohanty B, Ilyichova OV, Mulcair MD, Williams ML, Gleeson EC, Totsika M, Doak BC, Caria S, Rimmer K, Horne J, Shouldice SR, Vazirani M, Headey SJ, Plumb BR, Martin JL, Heras B, Simpson JS, Scanlon MJ Angew Chem Int Ed Engl. 2014 Dec 30. doi: 10.1002/anie.201410341. PMID:25556635[1] From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine. References
|
| ||||||||||||||||||